Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance

Luca Triggiani, Rosario Mazzola, Davide Tomasini, Alessio Bruni, Giulia Alicino, Fabio Matrone, Roberto Bortolus, Giulio Francolini, Beatrice Detti, Alessandro Magli, Marco Lorenzo Bonù, Gianluca Ingrosso, Andrea Lancia, Fabio Trippa, Ernesto Maranzano, Ciro Franzese, Paolo Ghirardelli, Vittorio Vavassori, Marta Scorsetti, Filippo AlongiStefano Maria Magrini

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the present study was to explore the potential impact of upfront metastases-directed therapy (MDT) in terms of prolongation of castration-sensitive phase in a series of oligorecurrent castration-sensitive prostate cancer (PC) patients. The present article is a multicenter retrospective study. The population of interest was castrate-sensitive oligorecurrent PC, defined as the presence of 1–3 uptakes in non-visceral sites such as bones or nodes detected by means of 18F-Choline PET/CT or 68-Gallium PSMA PET/CT. Primary endpoint was the time to castration resistance. Secondary endpoints were ADT-free survival, local progression-free survival, and overall survival. Eighty-two patients and 118 lesions were analyzed. The median time to castration resistance for the entire population of the study was 49 months (95% CI 43.6–54.4 months). The 1- and 2-year TTCR-free survival rates were 94% and 82%, respectively. At the time of analysis, 52 patients were still in the castration-sensitive phase of the disease. In this cohort of patients, the median ADT-free survival was 20 months (range 3–69 months). On the other hand, during follow-up 30 patients switched to the castration-resistant phase of disease. In this last group of patients, the median ADT-free survival was 20 months (range 4–50 months). After the ADT administration, the median castration-sensitive phase was 29 months (range 5–71 months). Castration resistance generally occurs at a median follow-up of 24–36 months following ADT. In the current study, upfront MDT does not decrease the time from initiation of ADT to castration resistance.

Original languageEnglish
Article number72
JournalMedical Oncology
Volume38
Issue number6
DOIs
Publication statusPublished - Jun 2021

Keywords

  • Metastasis directed therapy
  • Prostate cancer
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance'. Together they form a unique fingerprint.

Cite this